Medicare老年转移性前列腺癌患者ARPI时代死亡率变化:人群研究
该研究基于SEER-Medicare数据库,纳入9625例新诊断转移性前列腺癌患者(中位年龄78岁),比较ARPI前时代(2006-2012年)与ARPI时代(2013-2019年)的全因死亡率。部分改善可能源于分期迁移。
要点
- ARPI时代Medicare Part D覆盖患者中44.3%接受了ARPI治疗。
核心结论
- ARPI时代转移性前列腺癌患者全因死亡率风险降低约20%,但部分改善可能归因于分期迁移。
研究设计与样本
- 基于SEER-Medicare关联数据库的人群回顾性队列研究,纳入9625例新诊断转移性前列腺癌患者,中位年龄78岁。
关键数值与推荐
- ARPI时代Medicare Part D覆盖患者中44.3%接受了ARPI治疗。
临床怎么用
- 对于M1a和M1b期转移性前列腺癌老年患者,ARPI的应用与死亡率改善相关,支持在该人群中使用ARPI。
局限性
- 部分死亡率改善可能源于分期迁移,需谨慎解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine mortality and usage changes after the introduction of androgen receptor pathway inhibitors (ARPI) among older patients with metastatic prostate cancer covered by Medicare. MATERIALS AND METHODS: The study cohort, consisting of patients newly diagnosed with mPCa, was identified from the surveillance, epidemiology, and end results (SEER)-Medicare Linked Database. The primary outcome was all-cause mortality with time zero at the date of mPCa diagnosis. Patients were classified as pre-ARPI era if diagnosed with mPCa in 2006-2012 and ARPI era if diagnosed in 2013-2019. Mortality was summarized by unadjusted cumulative incidence and evaluated using covariate adjusted mortality hazard ratios (aHRs) from Cox proportional hazards regression modeling. RESULTS: This study included 9625 patients diagnosed with mPCa (median age 78 years). 44.3% of patients with Medicaid Part D coverage were prescribed therapies in the ARPI era. Stratification by stage revealed that patients with M1a and M1b disease experienced significantly decreased mortality (aHRs: M1a 0.77, 95% CI 0.60-0.98, P = .03; M1b 0.81, 0.77-0.86, P <.01; M1c 0.90, 0.80-1.01; P = .06). CONCLUSIONS: Since the introduction of ARPIs, the uptake among Medicare patients was relatively high. While we observed a significant 20% lower mortality hazard among patients diagnosed with mPCa after 2013 when ARPIs were introduced, some of the improvement might have resulted from stage migration.
引用
- Kim IE, Hartman R, Gandhi K, et al. Mortality in Medicare-aged Men With Metastatic Prostate Cancer After the Introduction of Androgen Receptor Pathway Inhibitors: A Population-based Study. Urology. 2026. PMID: 42551541. doi:10.1016/j.urology.2026.07.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。